Overview Pulmozyme in Cystic Fibrosis With Sinusitis Status: Withdrawn Trial end date: 2015-06-01 Target enrollment: Participant gender: Summary The hypothesis is that the intranasal use of Pulmozyme will decrease the severity of sinusitis in Cystic Fibrosis and lead to an improved quality of life. Phase: Phase 3 Details Lead Sponsor: Milton S. Hershey Medical CenterPenn State UniversityCollaborator: Genentech, Inc.